Non-invasive glioblastoma immunoprofiling by printed peptide arrays
Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arra...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 Feb 2016
|
| In: |
OncoImmunology
Year: 2016, Volume: 5, Issue: 2 |
| ISSN: | 2162-402X |
| DOI: | 10.1080/2162402X.2015.1069941 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/2162402X.2015.1069941
|
| Author Notes: | Andreas Mock and Christel Herold-Mende |
| Summary: | Immune monitoring assays for patient stratification and treatment efficacy in clinical trials are in demand. We have recently described a cost-effective non-invasive assay to determine the immune status of glioblastoma patients. Profiling antitumor serum antibodies by customized printed peptide arrays identified response against a tenascin-C (TNC) peptide as a robust prognostic biomarker. |
|---|---|
| Item Description: | Gesehen am 10.07.2020 |
| Physical Description: | Online Resource |
| ISSN: | 2162-402X |
| DOI: | 10.1080/2162402X.2015.1069941 |